96 related articles for article (PubMed ID: 18203022)
1. Germline mutations in RAD51, RAD51AP1, RAD51B, RAD51C,RAD51D, RAD52 and RAD54L do not contribute to familial chronic lymphocytic leukemia.
Sellick G; Fielding S; Qureshi M; Catovsky D; ; Houlston R
Leuk Lymphoma; 2008 Jan; 49(1):130-3. PubMed ID: 18203022
[TBL] [Abstract][Full Text] [Related]
2. Germline mutations in Dok1 do not predispose to chronic lymphocytic leukemia.
Sellick GS; Coleman RJ; Talaban RV; Fleischmann C; Rudd MF; Allinson R; Catovsky D; Houlston RS
Leuk Res; 2005 Jan; 29(1):59-61. PubMed ID: 15541476
[TBL] [Abstract][Full Text] [Related]
3. Germline mutation in the RAD51B gene confers predisposition to breast cancer.
Golmard L; Caux-Moncoutier V; Davy G; Al Ageeli E; Poirot B; Tirapo C; Michaux D; Barbaroux C; d'Enghien CD; Nicolas A; Castéra L; Sastre-Garau X; Stern MH; Houdayer C; Stoppa-Lyonnet D
BMC Cancer; 2013 Oct; 13():484. PubMed ID: 24139550
[TBL] [Abstract][Full Text] [Related]
4. BRG1 promotes the repair of DNA double-strand breaks by facilitating the replacement of RPA with RAD51.
Qi W; Wang R; Chen H; Wang X; Xiao T; Boldogh I; Ba X; Han L; Zeng X
J Cell Sci; 2015 Jan; 128(2):317-30. PubMed ID: 25395584
[TBL] [Abstract][Full Text] [Related]
5. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.
Cramer-Morales K; Nieborowska-Skorska M; Scheibner K; Padget M; Irvine DA; Sliwinski T; Haas K; Lee J; Geng H; Roy D; Slupianek A; Rassool FV; Wasik MA; Childers W; Copland M; Müschen M; Civin CI; Skorski T
Blood; 2013 Aug; 122(7):1293-304. PubMed ID: 23836560
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of miRNA-binding-site SNPs of MRE11A, NBS1, RAD51 and RAD52 involved in HRR pathway genes and risk of breast cancer in China.
Wu Z; Wang P; Song C; Wang K; Yan R; Li J; Dai L
Mol Genet Genomics; 2015 Jun; 290(3):1141-53. PubMed ID: 25566853
[TBL] [Abstract][Full Text] [Related]
7. Common nonsense mutations in RAD52.
Bell DW; Wahrer DC; Kang DH; MacMahon MS; FitzGerald MG; Ishioka C; Isselbacher KJ; Krainer M; Haber DA
Cancer Res; 1999 Aug; 59(16):3883-8. PubMed ID: 10463575
[TBL] [Abstract][Full Text] [Related]
8. Rad52, Maestro of Inverse Strand Exchange.
Kwon Y; Sung P
Mol Cell; 2017 Jul; 67(1):1-3. PubMed ID: 28686872
[TBL] [Abstract][Full Text] [Related]
9. ATM mutations are rare in familial chronic lymphocytic leukemia.
Yuille MR; Condie A; Hudson CD; Bradshaw PS; Stone EM; Matutes E; Catovsky D; Houlston RS
Blood; 2002 Jul; 100(2):603-9. PubMed ID: 12091354
[TBL] [Abstract][Full Text] [Related]
10. Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers.
Golmard L; Castéra L; Krieger S; Moncoutier V; Abidallah K; Tenreiro H; Laugé A; Tarabeux J; Millot GA; Nicolas A; Laé M; Abadie C; Berthet P; Polycarpe F; Frébourg T; Elan C; de Pauw A; Gauthier-Villars M; Buecher B; Stern MH; Stoppa-Lyonnet D; Vaur D; Houdayer C
Eur J Hum Genet; 2017 Dec; 25(12):1345-1353. PubMed ID: 29255180
[TBL] [Abstract][Full Text] [Related]
11. DNA damage during the G0/G1 phase triggers RNA-templated, Cockayne syndrome B-dependent homologous recombination.
Wei L; Nakajima S; Böhm S; Bernstein KA; Shen Z; Tsang M; Levine AS; Lan L
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):E3495-504. PubMed ID: 26100862
[TBL] [Abstract][Full Text] [Related]
12. Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families.
Johnson J; Healey S; Khanna KK; ; Chenevix-Trench G
Breast Cancer Res Treat; 2011 Aug; 129(1):255-63. PubMed ID: 21533530
[TBL] [Abstract][Full Text] [Related]
13. Rad52 gene mutations in breast/ovarian cancer families and sporadic ovarian carcinoma patients.
Tong D; Volm T; Eberhardt E; Krainer M; Leodolter S; Kreienberg R; Zeillinger R
Oncol Rep; 2003; 10(5):1551-3. PubMed ID: 12883740
[TBL] [Abstract][Full Text] [Related]
14. Molecular dissection of interactions between Rad51 and members of the recombination-repair group.
Krejci L; Damborsky J; Thomsen B; Duno M; Bendixen C
Mol Cell Biol; 2001 Feb; 21(3):966-76. PubMed ID: 11154282
[TBL] [Abstract][Full Text] [Related]
15. RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families.
Pelttari LM; Kiiski JI; Ranta S; Vilske S; Blomqvist C; Aittomäki K; Nevanlinna H
Springerplus; 2015; 4():92. PubMed ID: 25918678
[TBL] [Abstract][Full Text] [Related]
16. Ionizing radiation-induced foci formation of mammalian Rad51 and Rad54 depends on the Rad51 paralogs, but not on Rad52.
van Veelen LR; Essers J; van de Rakt MW; Odijk H; Pastink A; Zdzienicka MZ; Paulusma CC; Kanaar R
Mutat Res; 2005 Jul; 574(1-2):34-49. PubMed ID: 15914205
[TBL] [Abstract][Full Text] [Related]
17. Screening for RAD51 and BRCA2 BRC repeat mutations in breast and ovarian cancer families.
Rapakko K; Heikkinen K; Karppinen SM; Winqvist R
Cancer Lett; 2006 May; 236(1):142-7. PubMed ID: 16005565
[TBL] [Abstract][Full Text] [Related]
18. The RAD51 gene family, genetic instability and cancer.
Thacker J
Cancer Lett; 2005 Mar; 219(2):125-35. PubMed ID: 15723711
[TBL] [Abstract][Full Text] [Related]
19. A decade of RAD51C and RAD51D germline variants in cancer.
Boni J; Idani A; Roca C; Feliubadaló L; Tomiak E; Weber E; Foulkes WD; Orthwein A; El Haffaf Z; Lazaro C; Rivera B
Hum Mutat; 2022 Mar; 43(3):285-298. PubMed ID: 34923718
[TBL] [Abstract][Full Text] [Related]
20. Synergistic actions of Rad51 and Rad52 in recombination and DNA repair.
Benson FE; Baumann P; West SC
Nature; 1998 Jan; 391(6665):401-4. PubMed ID: 9450758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
